With Al­im­ta patent cliff loom­ing, Lil­ly plots stronger foothold in front­line NSCLC with Cyra­mza

With Lil­ly’s foothold in the non-small cell lung can­cer (NSCLC) field weak­en­ing as its Al­im­ta fran­chise march­es to­ward a patent cliff, an­oth­er can­cer treat­ment man­u­fac­tured by the drug­mak­er could be used as a front­line treat­ment in the lu­cra­tive mar­ket. On Tues­day, the In­di­anapo­lis com­pa­ny said its drug, Cyra­mza, in com­bi­na­tion with Roche’s Tarce­va, helped stem the spread and growth of can­cer as an ini­tial treat­ment in cer­tain pa­tients with metasta­t­ic NSCLC in a piv­otal study.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER